Servipep 20 - Tablet Famotidine - 20mg 10 Tablet(s) / Strip Nevian Lifescience PLC Introduction: Servipep 20 is an antacid. It reduces the amount of acid produced by your stomach. It is used to treat and prevent heartburn, indigestion and other symptoms caused by too much acid in the stomach. It is also used to treat and prevent stomach ulcers, reflux disease and some other rare conditions. Servipep 20 is also commonly prescribed to prevent stomach ulcers and heartburn caused due to the use of painkillers. It must be swallowed whole with water before or after a meal. The medicine must be taken in the dose and duration advised by the doctor. This medicine should... Uses of Servipep 20: Gastroesophageal reflux disease (Acid reflux)Peptic ulcer disease Side effects of Servipep 20: HeadacheDiarrheaConstipation How to use Servipep 20: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Servipep 20 is to be taken with food. How Servipep 20 works: Servipep 20 is a histamine H2 receptor antagonist. It works by reducing the acid produced in the stomach. This helps to relieve acid-related indigestion and heartburn. What if you forget to take Servipep 20?: If you miss a dose of Servipep 20, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose. Indication: Heartburn, Peptic ulcer, Dyspepsia, Urticaria, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD) Administration: May be taken with or without food. Reconstitution: For IV inj: Famotidine 20 mg is diluted to a total of 5 or 10 mL w/ NaCl 0.9% inj or dextrose 5% or 10% inj, lactated Ringer's, water for inj soln to provide a soln containing approx 4 or 2 mg/mL, respectively. For intermittent IV infusion: Famotidine 20 mg is added to dextrose 5% inj 100 mL or NaCl 0.9% inj, lactated Ringer's soln, water for inj soln to provide a soln containing approximately 0.2 mg/mL. IV Administration Infuse at rate no faster than 10 mg/min Adult Dose: Oral Benign gastric and duodenal ulceration Adult: 40 mg daily at bedtime for 4-8 wk or 20 mg bid. Maintenance: 20 mg at bedtime to prevent recurrence of duodenal ulceration. Gastro-oesophageal reflux disease Adult: 20 mg bid for 6-12 wk or up to 40 mg bid if there is oesophageal ulceration. Maintenance: 20 mg bid to prevent recurrence. Zollinger-Ellison syndrome Adult: Initially, 20 mg 6 hrly, up to 800 mg/day if necessary. Non-ulcer dyspepsia ; Heartburn Adult: 10-20 mg once or bid. Child Dose: Peptic Ulcer 1-16 years: 0.5 mg/kg PO at bedtime; not to exceed 40 mg/day Gastroesophageal Reflux Disease 12 years: 10-20 mg q12 hr; may take 15-60 min before eating foods that could cause heartburn Renal Dose: Renal impairment: CrCl (ml/min) Dosage Recommendation <50 Reduce the dose by half or increase dosing interval to 36-48 hr. Contraindication: Hypersensitivity. Mode of Action: Famotidine competitively blocks histamine at H2-receptors thus reducing basal, nocturnal and stimulated gastric acid secretion. Pepsin secretion is reduced resulting in decreased peptic activity. Precaution: Impaired renal function. Long term treatment should be avoided. Lactation: Drug enters breast milk; use not recommended Side Effect: 1-10% Headache (4.7%),Diarrhea (1.7%),Dizziness (1.3%),Constipation (1.2%) Frequency Not Defined Body as a whole: Fever, asthenia, fatigue Cardiovascular: Arrhythmia, AV block, palpitation; prolonged QT interval in patients with impaired renal function, has been reported very rarely Gastrointestinal: Cholestatic jaundice, hepatitis, liver enzyme abnormalities, vomiting, nausea, abdominal discomfort, anorexia, dry mouth Hematologic: Rare cases of agranulocytosis, pancytopenia, leukopenia, thrombocytopenia Hypersensitivity: Anaphylaxis, angioedema, orbital or facial edema, urticaria, rash, conjunctival injection Musculoskeletal: Rhabdomyolysis, musculoskeletal pain including muscle cramps, arthralgia Nervous system/psychiatric: Grand mal seizure; psychic disturbances, which were reversible in cases for which follow-up was obtained, including hallucinations, confusion, agitation, depression, anxiety, decreased... Pregnancy Category Note: Pregnancy Available data in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes Animal data Animal reproduction studies have shown no adverse development effects at doses up to approximately 243 times, the recommended human dose of 80 mg per day for treatment of erosive esophagitis Lactation There are limited data available on presence in human breast milk; there were no effects on breastfed infant; there are no data on famotidine effects on milk production; drug reported present in milk of lactating rats; developmental and health benefits of breastfeeding should... Interaction: Antacids slightly decrease the bioavailability of famotidine. May reduce serum concentration of ketoconazole and itraconazole.